Treatment initiation before 90 days correlated with markedly higher independent walking (73.2% vs 36.7%) and fewer ...
The investigators set out to indirectly compare nipocalimab's safety, specifically any adverse event (AE) and any serious ...
Cluster headache care remains hindered by migraine overlap, contributing to diagnostic delay and prolonged unmet need for ...
The professor of neurology at the University of Lyon and 2026 Rachel Horne Prize Winner discussed pregnancy counseling, ...
Congressional passage would extend ACT for ALS programs and associated research grants through FY2031, sustaining federal ...
The chairman of the Neurology Service Line at Baptist Health in Kentucky discusses PREVAIL findings on clinical deterioration, rescue therapy use, and hospitalization with gefurulimab in generalized ...
Tasimelteon advanced sleep onset by 42.5 minutes versus 5.4 minutes with placebo in DSWPD, meeting the primary endpoint with ...
A second on-label option carries its own distinct mechanism and its own trial history. The panel details how this ...
FcRn blockade with nipocalimab necessitates pregnancy surveillance because placental FcRn drives maternal–fetal IgG transfer, ...
A prospective, multicenter real-world study, dubbed ADHERE REAL (NCT07264426), will evaluate the effectiveness of ...
Findings from the phase 3 TransportNPC study showed that Trappsol Cyclo missed the primary end point in Niemann-Pick type C, but subgroup and survival data support planned 2026 NDA. The professor of ...
The FDA has approved tavapadon (AbbVie), a once-daily oral selective dopamine D1/D5 receptor partial agonist, for adults with ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results